Email: cspc@cspc.cn
News
News Center
Aug. 27
2026
VOLUNTARY ANNOUNCEMENT - HIGHLY POTENT AMYLIN RECEPTOR AGONIST (SYH2092 INJECTION) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
Aug. 26
VOLUNTARY ANNOUNCEMENT - PHASE III CLINICAL STUDY OF SYS6010 FOR EGFR-MUTATED LOCALLY ADVANCED OR METASTATIC NSCLC FOLLOWING FAILURE OF EGFR TKI THERAPY MEETS P
VOLUNTARY ANNOUNCEMENT - SYS6090 (JMT108) GRANTED FAST TRACK DESIGNATION BY U.S. FDA FOR TREATMENT OF PATIENTS WITH MSS/pMMR mCRC
Aug. 25
VOLUNTARY ANNOUNCEMENT - RECOMBINANT RESPIRATORY SYNCYTIAL VIRUS VACCINE (SYS6057) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
Aug. 19
VOLUNTARY ANNOUNCEMENT - PHASE IB/II CLINICAL TRIAL OF SYS6090 INJECTION FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA OFFICIALLY INITIATED AT THE FIRST CENTRE
Aug. 18
VOLUNTARY ANNOUNCEMENT - NEW DRUG APPLICATION FOR ANBENITAMAB (KN026) AND DOCETAXEL FOR INJECTION (ALBUMIN-BOUND) (HB1801) FOR THE FIRST-LINE TREATMENT OF ADVAN
Contact Us
Phone:
+86 311 8703 7015
Email:
cspc@cspc.cn
Products
Science
About Us